BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30618747)

  • 1. Therapeutic Potential of Nitrogen Mustard Based Hybrid Molecules.
    Chen Y; Jia Y; Song W; Zhang L
    Front Pharmacol; 2018; 9():1453. PubMed ID: 30618747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
    Singh RK; Kumar S; Prasad DN; Bhardwaj TR
    Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid-linked nitrogen mustards as potential anticancer therapeutics: a review.
    Saha P; Debnath C; Bérubé G
    J Steroid Biochem Mol Biol; 2013 Sep; 137():271-300. PubMed ID: 23692738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.
    Gao X; Li J; Wang M; Xu S; Liu W; Zang L; Li Z; Hua H; Xu J; Li D
    Eur J Med Chem; 2018 Feb; 146():588-598. PubMed ID: 29407983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel N-mustard-benzimidazoles/benzothiazoles Hybrids, Synthesis and Anticancer Evaluation.
    Detroja D; Chen TL; Lin YW; Yen TY; Wu MH; Tsai TH; Mehariya K; Kakadiya R; Lee TC; Shah A; Su TL
    Anticancer Agents Med Chem; 2017; 17(13):1741-1755. PubMed ID: 28530540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, structure-activity relationship and biological evaluation of novel nitrogen mustard sophoridinic acid derivatives as potential anticancer agents.
    Li DD; Dai LL; Zhang N; Tao ZW
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4092-6. PubMed ID: 26299348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends.
    Diethelm-Varela B; Ai Y; Liang D; Xue F
    Curr Top Med Chem; 2019; 19(9):691-712. PubMed ID: 30931858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards.
    Mattes WB; Hartley JA; Kohn KW
    Nucleic Acids Res; 1986 Apr; 14(7):2971-87. PubMed ID: 3960738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
    Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A
    Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard.
    Gourdie TA; Valu KK; Gravatt GL; Boritzki TJ; Baguley BC; Wakelin LP; Wilson WR; Woodgate PD; Denny WA
    J Med Chem; 1990 Apr; 33(4):1177-86. PubMed ID: 2319563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the development of hybrid anticancer drugs.
    Fortin S; Bérubé G
    Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking.
    Chen W; Han Y; Peng X
    Chemistry; 2014 Jun; 20(24):7410-8. PubMed ID: 24806710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance.
    Bramson J; McQuillan A; Aubin R; Alaoui-Jamali M; Batist G; Christodoulopoulos G; Panasci LC
    Mutat Res; 1995 May; 336(3):269-78. PubMed ID: 7739615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical factors in the action of phosphoramidic mustard alkylating anticancer drugs: roles for computational chemistry.
    Colvin ME; Sasaki JC; Tran NL
    Curr Pharm Des; 1999 Aug; 5(8):645-63. PubMed ID: 10469896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrogen Mustards as Alkylating Agents: A Review on Chemistry, Mechanism of Action and Current USFDA Status of Drugs.
    More GS; Thomas AB; Chitlange SS; Nanda RK; Gajbhiye RL
    Anticancer Agents Med Chem; 2019; 19(9):1080-1102. PubMed ID: 30834842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines.
    Palmer BD; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 1990 Jan; 33(1):112-21. PubMed ID: 2296009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of a new potential anticancer drug: a case history.
    Cozzi P
    Farmaco; 2003 Mar; 58(3):213-20. PubMed ID: 12620417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactions of nitrogen mustards with DNA.
    Hemminki K; Kallama S
    IARC Sci Publ; 1986; (78):55-70. PubMed ID: 3583398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and transport of oxazaphosphorines and the clinical implications.
    Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
    Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.